ArticleBlood neoplasia2025
Application of the International Working Group MDS molecular taxonomy classes to a single institution cohort.
Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopathology classification increasingly relies on genetics, but most myelodysplastic syndromes/neoplasms (MDS) remain classified based on morphologic criteria such as blasts and dysplasia. Recently, the MDS International Working Group (IWG) developed an MDS molecular taxonomy using a large international cohort. Here, we applied this taxonomy to a single-institution cohort of 392 patients with MDS and oligomonocytic chronic myelomonocytic leukemia (oCMML) receiving modern standard of care. Cases were also classified per International Consensus Classification (ICC) and World Health Organization (WHO) 5th edition (WHO5). All patients were assigned to a molecular class; TP53-complex karyotype (TP53-CK; 29%), IDH-STAG2 (14%), SF3B1 (9%), and No-event (6%) were the most frequent. Clinical presentation varied across classes, with oCMML being most frequent in biallelic-TET2 (bi-TET2) (42%), EZH2-ASXL1 (50%), and clonal cytopenia of undetermined significance (CCUS)-like classes (33%). Molecular classifications were stable; only 18% changed upon follow-up. Molecular classes showed significant differences in overall survival (OS). On multivariable analyses (MVAs) that included stem cell transplant, longer OS was seen with SF3B1, del5q, and bi-TET2; shorter OS was seen with TP53-CK and -7/SETBP1. In MVAs for WHO5 and ICC entities, oCMML2 was the only morphologically defined entity that affected OS. For predicting OS, IWG molecular classification had a Harrell's C-index of 0.75, compared with WHO5 and ICC Harrell's C-indices of 0.74 and 0.73, respectively. Altogether, these results show that the IWG molecular taxonomy can be applied in routine practice, with several classes exhibiting distinct clinical features and outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.